Abstract:

BACKGROUND: At present, the only effective treatment is liver transplantation, but donor shortage is the main problem of liver transplantation, artificial liver can be served as a support means of liver transplantation in the transition.
OBJECTIVE: To observe the security of new human hepatocytes hybrid bioartificial liver.
METHODS: Chinese human liver cell line 1 (CL-1) cells, under micro carrier microgravity, which were injected into all the contact perfusion bioreactor inoculation, combined with plasma perfusion of D-galactosamine triggering acute liver failure of model treatment. The closure, adverse reactions and changes of monitoring animal vital signs were observed during the treatment. CL-1cells in were obtained in the perfusion bioreactor were obtained after treatment. The cellular debris and cells were inoculated into the neck and back of nude mice, respectively, and then underwent comparison.
RESULTS AND CONCLUSION: The liquid leakage was not found in the circulation channel, hemorrhage, allergies, high fever and other serious adverse reactions were also not found, vital signs were smooth and steady during the treatment of acute liver failure of model of cynomolgus. After four weeks of inoculation, planting tumor was not seen in nude mice with cellular debris inoculation, 10 vaccinal place occured tumor in nude mice with cellular debris inoculation, tumors rate was 100%. New human hepatocytes hybrid bioartificial liver is safe and validity and its effectiveness can be further explored. It is expected to be used for various animal experiment researches and each period clinical study.